- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02164123
Autonomic Effects of T4 Mobilization in Asymptomatic Subjects
Autonomic Effects of T4 Mobilization in Asymptomatic Subjects: Randomized Clinical Trial
Study Overview
Status
Intervention / Treatment
Detailed Description
Asymptomatic subjects will be recruited to this study. Pressure pain threshold, heart rate, heart rate variability and skin conductance will be measured before, immediately after and fifteen minutes after the intervention.
Subjects will be randomized into three groups: Passive accessory intervertebral mobilization one, passive accessory intervertebral mobilization two and placebo group.
The researcher that will do the intervention will be blinded to the outcomes measures, and the researcher that will do the measurements will be blind to the intervention.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
RS
-
Porto Alegre, RS, Brazil, 90050-170
- Universidade Federal de Ciências da Saúde de Porto Alegre
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Asymptomatic subjects
- Aged between 18 - 40 years old
- Portuguese readers and writers
Exclusion Criteria:
- History of lesion or surgery to the spine
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Spinal mobilization
20 subjects will be randomized to this arm.
A postero-anterior (PA) mobilization, to the fourth thoracic vertebra will be applied, for 3 sets of one minute.
The subject will be comfortable prone lying.
|
Experimental group
Other Names:
|
|
Active Comparator: Spinal Mobilization II
20 subjects will be randomized to this arm.
A postero-anterior (PA) mobilization, to the fourth thoracic vertebra will be applied, for 3 sets of one minute, but in this case, the subject will be seated, in a position that influence the sympathetic trunk, at the thorax.
|
Active comparator group
Other Names:
|
|
Placebo Comparator: Placebo
20 subjects will be randomized to this arm.
Only manual contact will be applied, without any oscillation.
The subject will be comfortable prone lying.
The intervention time is the same of the other arms.
|
Placebo group
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Skin conductance
Time Frame: Change from Baseline imediately after, and 15 minutes after the intervention
|
Skin conductance will be measured with Biopac MP150, the electrodes will be attached to the third and fourth fingers bilaterally.
This measurement will be made during all the procedure, before, during and until 15 minutes after the intervention.
|
Change from Baseline imediately after, and 15 minutes after the intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pressure pain threshold
Time Frame: Change from Baseline imediately after, and 15 minutes after the intervention
|
Pressure pain threshold will be measured with a digital algometer (Model FDX 10; Wagner Instruments, Greenwich, CT).
This measurement will be made on the spinous process of C5 and T4, on the first dorsal interossei, and on the anterior tibial tuberosity bilaterally.
|
Change from Baseline imediately after, and 15 minutes after the intervention
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Heart rate variability
Time Frame: Change from Baseline imediately after the intervention
|
Heart rate variability will be measured with a Polar Advantage Interface (Polar Electro Oy, Kempele, Finland).
The belt will be positioned centrally, directly below the xiphisternum.
Heart rate data acquisition will me made for 5 minutes at baseline and for 5 minutes immediately after the intervention.
|
Change from Baseline imediately after the intervention
|
Collaborators and Investigators
Investigators
- Principal Investigator: Francisco De Araujo, Pt, Federal University of Health Science of Porto Alegre
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- UFCSPA-FXA-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Vertebra; Degeneration
-
NuVasiveCompletedSpinal Deformity | Spinal Trauma | Vertebra; DegenerationUnited States, Brazil
-
University of MichiganWashington University School of Medicine; LFR InternationalCompletedCervical Vertebra Injury | Cervical Vertebra FractureUnited States
-
Chang Gung Memorial HospitalCompletedLumbosacral Transitional VertebraTaiwan
-
University Hospital, BordeauxTerminated
-
Assiut UniversityUnknownOsteoporotic Fracture of Vertebra
-
Jiawei JiangRecruitingOsteoporotic Fracture of VertebraChina
-
Nexilis AGTerminatedOsteoporotic Fracture of VertebraAustria
-
MT Ortho s.r.l.CompletedOsteoporotic Fractures | Vertebra Compression FractureItaly
-
Medtronic Spinal and BiologicsCompletedPathological Fracture of Vertebra Due to Secondary Osteoporosis (Disorder) | Pathological Fracture of Vertebra Due to Neoplastic Disease (Disorder)China
-
University Hospital, Strasbourg, FranceRecruitingVertebra Compression FractureFrance
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
AkesoNot yet recruitingAtopic DermatitisChina
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
Chong Kun Dang PharmaceuticalUnknownHypertension | DyslipidemiasKorea, Republic of